No disclosed relationships extracted for OACCyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
We are a newly organized blank check company incorporated on June 28, 2024, as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination. While we may pursue an acquisition opportunity in any business, industry, sector, or geographical location, we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries. In particular, we intend to target North American, British or European companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors where our management has extensive investment experience. Our executive offices are located at 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071.
Nothing on the wire mentions OACC yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How OACC has moved on past release days vs its typical ±0.2% day, and how often it closed up. Computed from daily closes — not a forecast.